Related Experiment Videos
Protease-activated receptor 3 is a second thrombin receptor in humans
H Ishihara1, A J Connolly, D Zeng
1Cardiovascular Research Institute, University of California, San Francisco 94143-0130, USA.
Nature
|April 3, 1997
Summary
Researchers identified a new human thrombin receptor, protease-activated receptor 3 (PAR3). This discovery offers insights into thrombin signaling and potential therapeutic targets for vascular injury and inflammation.
Area of Science:
- Biochemistry
- Molecular Biology
- Cell Biology
Background:
- Thrombin, a key coagulation protease, activates various cells at vascular injury sites via G-protein-coupled receptors.
- Previous research indicated a second thrombin receptor in mouse platelets and tissue-specific receptor roles.
Purpose of the Study:
- To clone and characterize a novel human thrombin receptor.
- To investigate its role in cellular signaling and its potential as a therapeutic target.
Main Methods:
- Cloning and characterization of the new human thrombin receptor, PAR3.
- Assays to measure thrombin-triggered phosphoinositide hydrolysis.
- Analysis of PAR3 expression in human and mouse tissues.
Main Results:
- Identified and cloned a new human thrombin receptor, designated protease-activated receptor 3 (PAR3).
- Demonstrated that PAR3 mediates thrombin-triggered phosphoinositide hydrolysis.
- Confirmed PAR3 expression in human bone marrow and mouse megakaryocytes, suggesting its role as the second platelet thrombin receptor.
Conclusions:
- PAR3 is a novel human thrombin receptor involved in thrombin signaling.
- PAR3 is a potential candidate for the second platelet thrombin receptor.
- PAR3 presents a new target for therapeutics aimed at modulating thrombotic, inflammatory, and proliferative responses.